Taichung– Date July, 2023
YC Biotech Co., Ltd. recently partnered with Taichung Yien Clinic to host a successful training program for healthcare professionals, aimed at promoting DNA methylation cancer biomarker testing developed by EG BioMed Co., Ltd. This testing method offers a simple, rapid, and accurate approach, providing patients with a more comfortable diagnostic experience.
The event sparked active discussions among attendees. Medical staff from Taichung Yien Clinic expressed strong support for this innovative testing technology and shared their anticipation for the commercial availability of EG BioMed’s advanced cancer diagnostics.
As a pioneer in precision medicine, YC Biotech is dedicated to advancing innovative medical products and services. EG BioMed’s DNA methylation cancer biomarker testing represents a breakthrough in early cancer detection, enabling accurate results through a simple blood test. This approach significantly enhances treatment opportunities and survival rates for patients.
Through this collaboration, YC Biotech and Taichung Yien Clinic aim to promote the application of EG BioMed’s DNA methylation biomarker testing for breast cancer, ensuring access to advanced diagnostic tools for female patients at the clinic.
Taichung Yien Clinic is committed to delivering top-tier healthcare services and actively adopting new medical technologies. This partnership with YC Biotech will allow its patients to benefit from advanced cancer diagnostics, ensuring timely and precise treatment options.
Both parties look forward to contributing to the advancement of Taiwan’s medical technology through this collaboration. They also anticipate future opportunities to work together, striving to provide improved diagnostic and therapeutic services for cancer patients in Taiwan.